A New York Times article published on August 7, 2025, describes how the use of GLP-1 drugs, such as Ozempic and Wegovy, is influencing the food offerings of some restaurants in the United States. This phenomenon is particularly evident in establishments in St. Louis, where several locations have incorporated smaller-sized options or reduced prices for customers who consume less.
Examples include Clinton Hall, which offers a "teeny-weeny mini meal" (a mini burger, fries, and a drink) for $8, and bars serving scaled-down versions of cocktails like the "snaquiri," a small version of the daiquiri. Some establishments also offer free takeout boxes for leftovers, while others have adjusted their menus to allow half-portions.
According to an October 2024 PricewaterhouseCoopers report, between 8% and 10% of Americans already use GLP-1 medications, and up to 35% express interest in using them. This has reduced food and beverage consumption, especially indulgences like desserts and alcohol, which is impacting the business model of some restaurants.
The owners we interviewed point out that the challenge is maintaining profitability without sacrificing the dining experience. Strategies include diversifying menus, adjusting prices for smaller portions, and offering sharing options, all without losing the culinary identity.